55,186 TG Therapeutics, Inc. $TGTX Shares Sold by Penn Capital Management Company LLC

Penn Capital Management Company LLC trimmed its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 10.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 480,881 shares of the biopharmaceutical company’s stock after selling 55,186 shares during the period. TG Therapeutics comprises approximately 2.0% of Penn Capital Management Company LLC’s portfolio, making the stock its 3rd biggest holding. Penn Capital Management Company LLC’s holdings in TG Therapeutics were worth $26,876,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. acquired a new stake in TG Therapeutics during the second quarter valued at $1,211,429,000. Bank of America Corp DE acquired a new position in TG Therapeutics in the 2nd quarter worth about $71,960,000. Bank of New York Mellon Corp purchased a new stake in shares of TG Therapeutics during the 2nd quarter worth about $49,472,000. Dimensional Fund Advisors LP raised its stake in shares of TG Therapeutics by 129.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,084,855 shares of the biopharmaceutical company’s stock worth $36,029,000 after purchasing an additional 612,068 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in shares of TG Therapeutics by 697.6% during the 2nd quarter. Wellington Management Group LLP now owns 478,265 shares of the biopharmaceutical company’s stock worth $26,276,000 after purchasing an additional 418,300 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on TGTX shares. B. Riley Financial lifted their price target on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a report on Monday, July 27th. Weiss Ratings upgraded TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, November 4th. JPMorgan Chase & Co. increased their price objective on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Zacks Research raised shares of TG Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $78.00 target price on shares of TG Therapeutics in a research note on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $63.00.

TG Therapeutics Trading Up 5.9%

Shares of NASDAQ:TGTX opened at $63.38 on Tuesday. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. The stock has a market capitalization of $9.70 billion, a PE ratio of 23.13, a P/E/G ratio of 2.60 and a beta of 1.89. TG Therapeutics, Inc. has a 1 year low of $26.76 and a 1 year high of $63.60. The firm has a fifty day moving average price of $55.99 and a 200 day moving average price of $44.66.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.02). TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The company had revenue of $259.94 million for the quarter, compared to the consensus estimate of $245.47 million. During the same quarter last year, the business earned $2.43 earnings per share. TG Therapeutics’s quarterly revenue was up 60.8% on a year-over-year basis. Analysts expect that TG Therapeutics, Inc. will post 0.92 EPS for the current fiscal year.

Key Stories Impacting TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Third-quarter revenue was $259.9 million, up 60.8% year over year and above estimates of about $245.5 million. TG Therapeutics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its 2026 revenue outlook to $1.0 billion, ahead of the roughly $961 million consensus. CEO Michael Weiss also said global revenue could exceed $1 billion, with BRIUMVI driving growth. TG Therapeutics CEO sees global revenue exceeding $1B in 2026
• Neutral Sentiment: EPS was $0.35. That topped Zacks’ $0.28 estimate, but was below other reported consensus figures around $0.37; earnings were also lower than the $2.43 reported a year earlier. TG Therapeutics beats Q3 earnings and revenue estimates

Insider Activity

In other news, Director Laurence Charney sold 5,000 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $54.96, for a total transaction of $274,800.00. Following the transaction, the director owned 168,640 shares of the company’s stock, valued at approximately $9,268,454.40. This represents a 2.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 8.87% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions.

The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Headquartered in New York, TG Therapeutics serves patients in the United States and has expanded BRIUMVI’s availability into international markets, including Europe.